三鑫医疗收盘上涨2.28%，滚动市盈率20.62倍，总市值46.91亿元

Company Overview - Sanxin Medical focuses on the research, manufacturing, sales, and service of medical devices, with key products including blood purification devices, drug delivery devices, and cardiothoracic surgical products [2] - As of the end of 2024, the company holds 203 authorized patents, 121 pending patents, and has published 26 papers, demonstrating a strong commitment to technological innovation and R&D [2] Financial Performance - In Q1 2025, Sanxin Medical reported revenue of 361 million yuan, an increase of 8.88% year-on-year, and a net profit of 53.73 million yuan, reflecting a slight increase of 0.20% year-on-year [2] - The company's gross profit margin stands at 34.62% [2] Market Position - As of August 1, Sanxin Medical's stock closed at 8.98 yuan, with a rolling PE ratio of 20.62, marking a 553-day low, and a total market capitalization of 4.691 billion yuan [1] - The average PE ratio for the medical device industry is 53.65, with a median of 37.22, placing Sanxin Medical at the 45th position within the industry [1][3] Shareholder Information - As of March 31, 2025, Sanxin Medical has 18,367 shareholders, an increase of 1,327 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1]